ECSP961876A - PHARMACEUTICAL FORMULATIONS - Google Patents

PHARMACEUTICAL FORMULATIONS

Info

Publication number
ECSP961876A
ECSP961876A ECSP961876A ECSP961876A EC SP961876 A ECSP961876 A EC SP961876A EC SP961876 A ECSP961876 A EC SP961876A EC SP961876 A ECSP961876 A EC SP961876A
Authority
EC
Ecuador
Prior art keywords
darifenacin
pharmaceutically acceptable
patient
dosage form
pharmaceutical formulations
Prior art date
Application number
Other languages
Spanish (es)
Inventor
John Michael Humphrey
Thomas Francis Dolan
Donald John Nichols
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP961876 priority Critical patent/ECSP961876A/en
Publication of ECSP961876A publication Critical patent/ECSP961876A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El invento proporciona una forma de dosificación farmacéutica adaptada para la administración en el tracto gastrointestinal de un paciente que comprende darifenacina, o una de sus sales farmacéuticamente aceptable y un adyuvante diluyente o vehículo farmacéuticamente aceptable caracterizada porque la forma de dosificación está adaptada para liberar al menos el 10% en peso de la darifenacina o de su sal farmacéuticamente aceptable, en el tracto gastrointestinal inferior del paciente. La formulación minimiza los efectos secundarios indeseados y aumenta la biodisponibilidad de la darifenacina.The invention provides a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient comprising darifenacin, or a pharmaceutically acceptable salt thereof and a diluting adjuvant or pharmaceutically acceptable carrier characterized in that the dosage form is adapted to release at least 10% by weight of darifenacin or its pharmaceutically acceptable salt, in the patient's lower gastrointestinal tract. The formulation minimizes unwanted side effects and increases the bioavailability of darifenacin.

ECSP961876 1996-09-13 1996-09-13 PHARMACEUTICAL FORMULATIONS ECSP961876A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP961876 ECSP961876A (en) 1996-09-13 1996-09-13 PHARMACEUTICAL FORMULATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP961876 ECSP961876A (en) 1996-09-13 1996-09-13 PHARMACEUTICAL FORMULATIONS

Publications (1)

Publication Number Publication Date
ECSP961876A true ECSP961876A (en) 1997-11-28

Family

ID=42042602

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP961876 ECSP961876A (en) 1996-09-13 1996-09-13 PHARMACEUTICAL FORMULATIONS

Country Status (1)

Country Link
EC (1) ECSP961876A (en)

Similar Documents

Publication Publication Date Title
CO4750822A1 (en) TADA PHARMACEUTICAL FORMULATIONS FOR THE ADMINISTRATION IN THE GASTROINTESTINAL TRACT AND PROCESSES TO PREPARE THE SAME
AR035927A1 (en) LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
CY1112260T1 (en) CONTROLLED HYDROCONUT PACKAGES
BR9508687A (en) Sustained release of peptides from pharmaceutical compositions
RU94032150A (en) Medicinal agent exhibiting delayed release of active-acting substance
ATE129404T1 (en) DOSAGE FORM FOR THE RELEASE OF A MEDICINE IN A SHORT PERIOD.
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
AR004700A1 (en) 1ALFA, 26 DIHIDROXI-D-HOMO-VITAMIN D3, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A PROCEDURE FOR ITS PREPARATION AND USE OF THEM IN THE ELABORATION OF A MEDICINAL PRODUCT
KR930009605A (en) Anti-inflammatory or analgesic
AR011919A1 (en) FORMULATION IN TABLETS OR SWALLOWING CAPSULES OF PARACETAMOL (N-ACETIL-P-AMINOFENOL) AND PROCEDURE TO PREPARE IT
AR036312A1 (en) PHARMACEUTICAL COMPOSITION
AR035006A1 (en) DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR011437A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MIGRANES AND THE USE OF THE SAME IN THE PREPARATION OF A MEDICINAL PRODUCT.
ECSP961876A (en) PHARMACEUTICAL FORMULATIONS
ES2151922T3 (en) USE OF ASPIRINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO IMPROVE BLOOD PERFUSION IN THE UTERUS.
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
ES2356371T3 (en) THERAPEUTIC MEDICINES TO INDUCE TOLERANCE.
AR022338A1 (en) A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT.
HUP0400495A2 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
BR0112690A (en) Cilansetron-containing drug for the treatment of non-constipative male ibs patients
ES2101311T3 (en) USE OF A TRANSDERMIC DEVICE CONTAINING (E) -2- (P-FLUOROFENETIL) -3-FLUOROALILAMINA AND ITS USE FOR THE TREATMENT OF ALZHEIMER DISEASE.
ES2135424T3 (en) ORAL COMPOSITION BASED ON IBUPROFEN.
ECSP982520A (en) COMPOSITION
CO5160246A1 (en) METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONS